Tue, March 9, 2021, 8:45 AM
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.
"We are pleased to welcome Betsy and Andrew to our Board at a critical time for Exicure, having made significant progress with the development of cavrotolimod in oncology and XCUR-FXN in Friedreich’s ataxia. Betsy’s distinguished career and significant clinical development experience and Andrew’s financial and institutional investor experience will provide important perspective to our Board," said Timothy P. Walbert, Exicure’s Chairman of the Board of Directors. "We look forward to the collective experience they will bring as Exicure advances its pipeline of innovative investigational therapies and we look to deliver on the promise of Exicure’s proprietary Spherical Nucleic Acid, or SNA technology."
Dr. Garofalo is a biopharma executive with more than 25 years of experience in global clinical development and regulatory affairs. Since 2016, Dr. Garofalo has served as the principal for EAG Pharma Consulting LLC. Prior to then, she served in numerous leadership roles including as Senior Vice President and Global Head of Clinical Development for Novartis and as a member of its Global Development Leadership Team, Chair of the Novartis Portfolio Stewardship Board, Co-Head of the Novartis Neuroscience Franchise, Head of the Neuroscience Therapy Area at Astellas, Ann Arbor Site Head of Worldwide Regulatory Affairs at Pfizer and Ann Arbor Site Head of Neuroscience at Pfizer.
Dr. Garofalo currently serves on the Board of Acadia Pharmaceuticals Inc., the Institute for Advanced Clinical Trials in Children and is the Chair of the Business Advisory Board for the Epilepsy Foundation of America. She has an M.D. from the Indiana University School of Medicine and completed fellowships in pediatric neurology and epilepsy at the University of Michigan Medical School.
"I am excited to be joining the Board of Exicure," said Dr. Garofalo. "The Exicure SNA platform technology offers great promise of producing new therapeutics directed towards neurological diseases with high unmet medical need and high morbidity."
Andrew Sassine currently serves as Chief Financial Officer and member of the board of directors of Arcturus Therapeutics. He also serves on the board of directors of ICAD, Inc., a cancer detection software company utilizing artificial intelligence. He previously was a fund manager at Fidelity Investments where he managed the Fidelity Small Cap Stock Fund and the Fidelity International Small Cap Opportunities Fund. He has an M.B.A. from the Wharton School at the University of Pennsylvania.
_____________________
OK so with this I have been studying Arcturus Therapeutics. They have an interesting approach to delivery of drug but as I see this their approach might be too toxic to the liver. Why do I say this? .......
note > SAN DIEGO--(BUSINESS WIRE)--Feb. 22, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company has acquired an exclusive license from Alexion Pharmaceuticals to certain patent-pending inventions relating to nucleic acid purification technologies.
Since the Company’s inception in 2013, Arcturus has been building proprietary expertise related to the manufacture of RNA through technological innovation. The licensed inventions enable larger scale and faster production of mRNA. The technology supports the Company’s efforts to optimize the highly efficient manufacture of mRNA therapeutic candidates with an increased purity profile. This acquisition extends the substantial intellectual property portfolio already held by Arcturus for the manufacture of high purity pharmaceutical quality mRNA therapeutic candidates for a variety of diseases.
Is it possible Exicure has the perfect delivery system for Arcturus Therapeutics
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.
"We are pleased to welcome Betsy and Andrew to our Board at a critical time for Exicure, having made significant progress with the development of cavrotolimod in oncology and XCUR-FXN in Friedreich’s ataxia. Betsy’s distinguished career and significant clinical development experience and Andrew’s financial and institutional investor experience will provide important perspective to our Board," said Timothy P. Walbert, Exicure’s Chairman of the Board of Directors. "We look forward to the collective experience they will bring as Exicure advances its pipeline of innovative investigational therapies and we look to deliver on the promise of Exicure’s proprietary Spherical Nucleic Acid, or SNA technology."
Dr. Garofalo is a biopharma executive with more than 25 years of experience in global clinical development and regulatory affairs. Since 2016, Dr. Garofalo has served as the principal for EAG Pharma Consulting LLC. Prior to then, she served in numerous leadership roles including as Senior Vice President and Global Head of Clinical Development for Novartis and as a member of its Global Development Leadership Team, Chair of the Novartis Portfolio Stewardship Board, Co-Head of the Novartis Neuroscience Franchise, Head of the Neuroscience Therapy Area at Astellas, Ann Arbor Site Head of Worldwide Regulatory Affairs at Pfizer and Ann Arbor Site Head of Neuroscience at Pfizer.
Dr. Garofalo currently serves on the Board of Acadia Pharmaceuticals Inc., the Institute for Advanced Clinical Trials in Children and is the Chair of the Business Advisory Board for the Epilepsy Foundation of America. She has an M.D. from the Indiana University School of Medicine and completed fellowships in pediatric neurology and epilepsy at the University of Michigan Medical School.
"I am excited to be joining the Board of Exicure," said Dr. Garofalo. "The Exicure SNA platform technology offers great promise of producing new therapeutics directed towards neurological diseases with high unmet medical need and high morbidity."
Andrew Sassine currently serves as Chief Financial Officer and member of the board of directors of Arcturus Therapeutics. He also serves on the board of directors of ICAD, Inc., a cancer detection software company utilizing artificial intelligence. He previously was a fund manager at Fidelity Investments where he managed the Fidelity Small Cap Stock Fund and the Fidelity International Small Cap Opportunities Fund. He has an M.B.A. from the Wharton School at the University of Pennsylvania.
_____________________
OK so with this I have been studying Arcturus Therapeutics. They have an interesting approach to delivery of drug but as I see this their approach might be too toxic to the liver. Why do I say this? .......
note > SAN DIEGO--(BUSINESS WIRE)--Feb. 22, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company has acquired an exclusive license from Alexion Pharmaceuticals to certain patent-pending inventions relating to nucleic acid purification technologies.
Since the Company’s inception in 2013, Arcturus has been building proprietary expertise related to the manufacture of RNA through technological innovation. The licensed inventions enable larger scale and faster production of mRNA. The technology supports the Company’s efforts to optimize the highly efficient manufacture of mRNA therapeutic candidates with an increased purity profile. This acquisition extends the substantial intellectual property portfolio already held by Arcturus for the manufacture of high purity pharmaceutical quality mRNA therapeutic candidates for a variety of diseases.
Is it possible Exicure has the perfect delivery system for Arcturus Therapeutics
